Nivolumab and ipilimumab: added benefit in pleural mesothelioma with non-epithelioid tumour histology

IQWiG

1 October 2021 - For the first time, a pure antibody combination has been approved as a first-line therapy for non-resectable malignant pleural mesothelioma. An additional clinical benefit has not been proven for those affected with epithelioid histology.

The monoclonal antibodies nivolumab and ipilimumab have already undergone several early benefit assessments in various oncological application areas.

Read IQWiG press release [German]

Michael Wonder

Posted by:

Michael Wonder